A practical reference on lyophilization: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-25 and is reviewed periodically as new material appears.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue with a C-terminal Pro-Gly-Pro tail |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Abbreviated TKPRPGP in most catalogues |
| Molecular mass | About 752 Da | Value for the free peptide |
| Solubility | Freely soluble in water | Aqueous solutions are kept cold and used promptly |
| Typical storage | -20 °C, dry, protected from light | Applies to the lyophilised powder before reconstitution |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Illicit drug trafficking in the West Indian Ocean (WIO) has increasingly become a major security concern for many States in the region, and is gaining international attention. The Indian Ocean borders 24 states, and accounts for a third of the world’s ocean area. Until recently, other challenges, such as piracy off the coast of Somalia, has been at the forefront of international action. However, the utilisation of the Southern route by drug traffickers, and the consequent issues this has caused, has led to increased focus on how to tackle this issue. The two main producers of heroin for the global market are frequently referred to as the Golden Triangle, including Myanmar, Thailand and Laos, and the Golden Crescent, which includes Afghanistan, Pakistan and Iran. Specifically Afghanistan and Pakistan as the two largest heroin and opium producers and exporters via the WIO. The three traditional ways of drug trafficking out of Afghanistan are; the Balkan route through Iran and Turkey via Eastern Europe to western and central European markets; the Northern Route via central Asia to Russia; and the Southern Route through Pakistan and across the Indian Ocean to Eastern African States and onward to consumer markets predominantly in Europe, Asia and the US. The increased use of the southern route via the WIO may be contributed to many factors, including better law enforcement on land-based routes, and the relatively weak enforcement measures concerning trafficking at sea.
== Professional activities == After earning a Ph.D. degree in biochemistry, a medical degree, and completing a research postdoctoral fellowship at the University of Wisconsin–Madison, Holick completed a residency in medicine at the Massachusetts General Hospital in Boston. He has been practicing adult and pediatric endocrinology since 1978 and is professor of medicine, physiology and biophysics and director of the Bone Health Care Clinic and the Heliotherapy, Light, and Skin Research Center at Boston University Medical Center. It provides extensive evaluation and treatment programs for children and adults with various metabolic bone diseases including osteoporosis, osteomalacia, stress fractures in young athletic women and men, and minimum trauma and nontraumatic fractures in infants, children and adults with hypermobility syndromes, osteogenesis imperfecta, and Ehlers–Danlos syndrome. He has been director of the General Clinical Research Unit at Boston University for several years. Holick serves as chair of NASA's "Human Health Countermeasures Element" Standing Review Panel, chair of the Endocrine Practice Guidelines Committee for Vitamin D, and editor-in-chief of the medical journal Clinical Laboratory.
=== Taxonomy === Salvia divinorum was first documented in 1939; yet, it was many years before botanists could identify the plant due to Mazatec secrecy about the growing sites. Flowers were needed for a definitive identification of the species. In 1962, the Swiss chemist Albert Hofmann and ethnomycologist R. Gordon Wasson traveled throughout the Sierra Mazateca researching Mazatec rituals while looking for specimens of the plant. They were unable to locate live plants. Eventually, the Mazatec provided them some flowering specimens. These specimens were sent to botanists Carl Epling and Carlos D. Játiva, who described and named the plant as Salvia divinorum, in reference to its use in divination and healing by the Mazatec. By 1985, up to fifteen populations of the plant had been located. Until 2010, there were differing opinions as to whether Salvia divinorum is an interspecific hybrid. The plant's partial sterility was suggestive of a hybrid origin, though no two parent species have been found with an obvious affinity to Salvia divinorum. One other possibility for the plant's partial sterility is that long-term cultivation and selection have produced an inbred cultigen. In 2010, a molecular phylogenetic approach by DNA sequencing of Salvia divinorum and a number of related species suggested that the species is not a hybrid. One earlier proposed parent was Salvia cyanea (a synonym for Salvia concolor), which Epling and Játiva believed to be closely allied to Salvia divinorum.
=== Neurotoxicity === Selegiline has been reported to protect against the damage caused by the potent dopaminergic and/or noradrenergic neurotoxins 6-hydroxydopamine (6-OHDA), N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4), and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in animals. Conversely, selegiline is ineffective in protecting against the serotonergic and noradrenergic neurotoxin 5,7-dihydroxytryptamine (5,7-DHT). Selegiline has also been reported to protect against methylenedioxymethamphetamine (MDMA)-induced serotonergic neurotoxicity in rodents. The serotonergic neurotoxicity of MDMA appears to be dependent on release of dopamine and its subsequent metabolism by MAO-B within serotonergic neurons into hydroxyl radicals, which is blocked by MAO-B inhibition. Likewise, selegiline prevented the serotonergic neurotoxicity of a combination of methylenedioxyaminoindane (MDAI) and dextroamphetamine. Conversely, selegiline failed to reduce the serotonergic neurotoxicity caused by fenfluramine and either did not affect or potentiated the serotonergic neurotoxicity caused by para-chloroamphetamine (PCA). In addition, findings are mixed and conflicting on whether selegiline prevents amphetamine- and methamphetamine-induced dopaminergic neurotoxicity in rodents. Although MAO-B-selective doses of selegiline protect against MDMA-induced serotonergic neurotoxicity in rodents, combination of amphetamines like MDMA with MAOIs, including selegiline, can produce serious complications, including serotonin syndrome, hypertensive crisis, and death.
Sources: en.wikipedia.org
== Signs and symptoms == The lesion is usually painless. The usual appearance is of two excess tissue folds in alveolar vestibule/buccal sulcus, with the flange of the denture fitting in between the two folds. It may occur in either the maxillary or mandibular sulci, although the latter is more usual. Anterior locations are more common than posterior. Less commonly there may be a single fold, and the lesion may appear on the lingual surface of the mandibular alveolar ridge. The swelling is firm and fibrous, with a smooth, pink surface. The surface may also show ulceration or erythema. The size of the lesion varies from less than 1 cm to involving the entire length of the sulcus.
The black-necked spitting cobra (Naja nigricollis) is a species of spitting cobra found mostly in Sub-Saharan Africa. They possess medically significant venom, although the mortality rate for untreated bites on humans is relatively low (~5–10%). Like other spitting cobras, this species is known for its ability to project venom at a potential threat. The venom is an irritant to the skin and eyes. If it enters the eyes, symptoms include extreme burning pain, loss of coordination, partial loss of vision and permanent blindness. N. nigricollis is known for its tendency to liberally spit venom with only the slightest provocation. However, this aggressiveness is counterbalanced by it being less prone to bite than other related species. The venom of the black-necked spitting cobra is somewhat unique among elapids in that it consists primarily of cytotoxins, but with other components also. It retains the typical elapid neurotoxic properties while combining these with highly potent cytotoxins (necrotic agents) and cardiotoxins. Bite symptoms include severe external hemorrhaging and tissue necrosis around the bite area and difficulty breathing. Although mortality rate in untreated cases is low (~5–10%), when death occurs it is usually due to asphyxiation by paralysis of the diaphragm. The LD50 of this species is 2 mg/kg SC and 1.15 mg/kg IV. The average venom yield per bite of this species is 200 to 350 mg (dry weight) according to Minton (1974).
Tyne and Wear () is a ceremonial county in North East England. It borders Northumberland to the north and County Durham to the south. The county contains the two cities of Newcastle upon Tyne and Sunderland. The notable towns in the county are Birtley, Blaydon Felling, Gateshead, Hebburn, Hetton-le-Hole, Houghton-le-Spring, Jarrow, Killingworth, North Shields, South Shields, Tynemouth, Wallsend, Washington and Whitley Bay. The county is largely urbanised, with an area of 540 square kilometres (210 sq mi) and an estimated population of 1,178,389 in 2024. Newcastle is on the north bank of the River Tyne in the centre of the county, and Gateshead opposite on the south bank. South Shields lies in the east at the river's mouth, and the city of Sunderland in the south-east at the mouth of the River Wear. Nearly all of the county's settlements belong to the Tyneside or Wearside conurbations, the latter of which extends into County Durham. For local government purposes Tyne and Wear comprises five metropolitan boroughs: Gateshead, Newcastle upon Tyne, Sunderland, North Tyneside and South Tyneside. The borough councils collaborate through the North East Combined Authority, which also includes Durham County Council and Northumberland County Council. The county was created in 1974 from south-east Northumberland and north-east County Durham. The most notable geographic features of the county are the River Tyne and River Wear, after which it is named and along which its major settlements developed.
Sources: en.wikipedia.org
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.
Tuftsin is a natural tetrapeptide derived from the Fc portion of immunoglobulin G. Selank retains that tetrapeptide at its N-terminus and adds three residues to improve resistance to enzymatic breakdown. The relationship is structural, and the two molecules are not interchangeable in experimental work.
It holds a product registration in Russia for intranasal use as an anxiolytic. Registrations of that kind are not automatically accepted by regulators elsewhere. In most other countries it is treated as an unapproved substance or a research material.
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.